Cardarine comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Following settlement in northward regions of Asia and Europe which seasonally get less sunlight, the selective pressure for radiation-protective skin tone decreased while a need for efficient vitamin D synthesis in skin increased, resulting in low-melanin, lighter skin tones in the rest of the prehistoric world. For people with low skin melanin, moderate sun exposure to the face, arms and lower legs several times a week is sufficient. However, for recent cultural changes such as indoor living and working, UV-blocking skin products to reduce the risk of sunburn and emigration of dark-skinned people to countries far from the equator have all contributed to an increased incidence of vitamin D insufficiency and deficiency that need to be addressed by food fortification and vitamin D dietary supplements.
1. Psychiatric Studies (1902–1906) 2. Experimental Researches (1904–1910) (trans L. Stein and D. Riviere) 3. Psychogenesis of Mental Disease (1907–1914; 1919–1958) 4. Freud and Psychoanalysis (1906–1914; 1916–1930) 5. Symbols of Transformation (1911–1912; 1952) 6. Psychological Types (1921) 7. Two Essays on Analytical Psychology (1912–1928) 8. Structure and Dynamics of the Psyche (1916–1952) 9.1 Archetypes and the Collective Unconscious (1934–1955) 9.2 Aion: Researches into the Phenomenology of the Self (1951) 10. Civilization in Transition (1918–1959) 11. Psychology and Religion: West and East (1932–1952) 12. Psychology and Alchemy (1936–1944) 13. Alchemical Studies (1919–1945) 14. Mysterium Coniunctionis (1955–1956) 15. Spirit in Man, Art, and Literature (1929–1941) 16. The Practice of Psychotherapy (1921–1925) 17. The Development of Personality (1910; 1925–1943) 18. The Symbolic Life: Miscellaneous Writings 19. General Bibliography 20. General Index Supplementary volumes
== In media == A boat train at Dover Western Docks station is seen in the third episode of Inspector Morse, "Deceived by Flight", which was filmed in 1989, prior to the station's closure in November 1994. The BBC's automotive TV programme Top Gear filmed an episode at the former hoverport, in which the presenters used amphibious cars to cross the English Channel.
== Structure == Graphene is a single layer of carbon atoms tightly bound in a hexagonal honeycomb lattice. It is an allotrope of carbon in the form of a plane of sp2-bonded atoms with a molecular bond length
=== Decreased MPV === Cytotoxic chemotherapy Hypersplenism Reactive thrombocytosis Iron-deficiency anemia Gilbert's syndrome Acquired Immunodeficiency Syndrome (AIDS) Wiskott–Aldrich syndrome X linked thrombocytopenia Crohn's disease Ulcerative colitis Aplastic anemia Megaloblastic anemia
Sources: en.wikipedia.org
Through this method, researchers can more effectively improve the functional properties of proteins to meet specific biotechnology or medical needs. Although this method has high requirements for information and technology and is relatively difficult to implement, with the development of computing technology and bioinformatics, the application prospects of semi-rational design in protein engineering are becoming more and more broad.
=== Extracellular matrix adhesion and signaling === Integrin alpha-1 (ITGA1), when linked with Integrin beta-1 (ITGB1), forms the α1β1 Integrin receptor. The α1β1 is a transmembrane extracellular matrix (ECM) receptor that mediates cell adhesion and intracellular signaling. By binding collagen and laminin, ITGA1 allows cells to sense and respond to changes in the ECM. These interactions are how ITGA1 regulates cell-matrix adhesion, focal adhesion formation, ECM organization, and downstream pathways controlling cell survival, proliferation, migration, and differentiation. The molecular functions of ITGA1 include collagen binding, collagen-mediated cell-matrix adhesion, protein interactions involved in signaling pathways, and localizations to the cell surface, plasma membrane, focal adhesions, and integrin complexes. These attributes aid in its function as a key mediator of ECM-dependent cellular communication.
Several reactions have been noted in manufacturer guidelines—deep sleep, incoordination, sedation, and dizziness have been reported in children and adults, as well as others such as hypotension, tinnitus, and headaches. Gastrointestinal effects have also been observed, as well as less serious effects such as dryness of the mouth and constipation caused by the mild antimuscarinic properties of hydroxyzine. Central nervous system effects such as hallucinations or confusion have been observed in rare cases, attributed mostly to overdosage. Such properties have been attributed to hydroxyzine in several cases, particularly in patients treated for neuropsychological disorders, as well as in cases where overdoses have been observed. While there are reports of hallucinogenic effects from use of hydroxyzine, several clinical data trials have not reported such side effects from the sole consumption of hydroxyzine, but rather, have described its overall calming effect through the stimulation of areas within the reticular formation. The hallucinogenic or hypnotic properties have been described as being an additional effect from overall central nervous system suppression by other CNS agents, such as lithium or ethanol. Hydroxyzine exhibits anxiolytic and sedative properties in many psychiatric patients. One study showed that patients reported very high levels of subjective sedation when first taking the drug, but that levels of reported sedation decreased markedly over 5–7 days, likely due to CNS receptor desensitization.
=== First House passage === Following markups by various House committees on their relevant portions of the bill, the House Budget Committee met on May 16, 2025, to combine the various markups into a single reconciliation bill. Some fiscally conservative Republicans opposed the bill over a desire for greater spending cuts, and the bill was rejected in a 21–16 vote, with representatives Chip Roy of Texas, Ralph Norman of South Carolina, Andrew Clyde of Georgia, and Josh Brecheen of Oklahoma joining all Democratic committee members to vote against it. Republican Lloyd Smucker of Pennsylvania changed his vote from yes to no so that he would be allowed to bring a motion to reconsider the bill at a later time. On May 18, the Budget Committee voted to advance the bill in a 17–16 vote. Roy, Norman, Clyde, and Brecheen changed their votes to present after House Republican leadership agreed to make Medicaid work requirements—previously scheduled to begin in 2029—kick in sooner and decrease future subsidies for clean energy. Despite this, the four Republicans said they would not support the bill's final passage unless more changes were made. Republicans did not secure these votes until May 21, when the bill was amended. On the morning of May 22, the United States House of Representatives passed OBBBA by a vote of 215–214–1, mostly along party lines. Fiscally conservative Republicans Thomas Massie and Warren Davidson broke from their party to vote against the bill. Freedom Caucus chair Andy Harris of Maryland voted present.
In the United States, a group of companies including OpenAI, Alphabet, and Meta signed a voluntary agreement with the Biden administration in July 2023 to watermark AI-generated content. In October 2023, Executive Order 14110 applied the Defense Production Act to require all US companies to report information to the federal government when training certain high-impact AI models. In the European Union (EU), the Artificial Intelligence Act includes requirements to disclose copyrighted material used to train generative AI systems, and to label any AI-generated output as such. In China, the Interim Measures for the Management of Generative AI Services introduced by the Cyberspace Administration of China regulates any public-facing generative AI. It includes requirements to watermark generated images or videos, regulations on training data and label quality, restrictions on personal data collection, and a guideline that generative AI services must "adhere to socialist core values". In 2021, UNESCO adopted the Recommendation on the Ethics of Artificial Intelligence, the first global standard-setting instrument on AI. It provides guidance to member states on issues including human rights, fairness, transparency, data governance, and environmental sustainability. The Group of Seven (G7) launched the Hiroshima AI Process in 2023, which produced international guiding principles and a voluntary code of conduct for developers of advanced AI systems.
Sources: en.wikipedia.org
The technology was originally developed by Elan Drug Technologies, a business unit of Elan Corporation, plc; Alkermes acquired the technology when it purchased Elan's drug delivery unit in 2011 for approximately $960 million. Nanocrystals of paliperidone palmitate form a depot or reservoir in the muscle. The 3-month formulation of paliperidone palmitate, Invega Trinza or Trevicta, has larger crystal sizes than the 1-month formulation, which dissolve more slowly at the injection site, allowing for its longer duration.
Morea began a relationship with actress Bipasha Basu in 1996. The two worked together in multiple films and modeling assignments. In 1998, an advertisement for the Swiss undergarment brand Calida featuring Morea and Basu drew controversy for its content and was subsequently withdrawn. The couple ended their relationship shortly after the release of Raaz (2002). He was briefly in a relationship with actress and model Lara Dutta from 2008 to 2009. From 2010 to 2017, he was in a relationship with designer Nandita Mahtani. In 2025, Morea confirmed he was in a relationship with Malaika Arora.
Alpha-synuclein primary structure is usually divided in three distinct domains: Residues 1-60: An amphipathic N-terminal region dominated by four 11-residue repeats including the consensus sequence KTKEGV. This sequence has a structural alpha helix propensity similar to apolipoproteins-binding domains. It is a highly conserved terminal that interacts with acidic lipid membranes, and all the discovered point mutations of the SNCA gene are located within this terminal. Residues 61-95: A central hydrophobic region which includes the non-amyloid-β component (NAC) region, involved in protein aggregation. This domain is unique to alpha-synuclein among the synuclein family. Residues 96-140: a highly acidic and proline-rich region which has no distinct structural propensity. This domain plays an important role in the function, solubility and interaction of alpha-synuclein with other proteins.
Preparing TNP-ATP is a one-step synthesis that is relatively safe and easy. Adenosine's ribose moiety can be trinitrophenylated by 2,4,6-trinitrobenzene-1-sulfonate (TNBS). The resulting compound assumes a bright orange color and has visible absorption characteristics, as is characteristic of a Meiseinheimer spiro complex compound linking. To see the exact method of preparion, please refer to T. Hiratsuka's and K. Uchida's paper "Preparation and Properties of 2'(r 3')-O(2,4,6-trinitrophenyl) Adenosine 5'-triphosphate, an Analog of Adenosine Triphosphate," found in the reference section. To revert TNP-ATP back to its constituent parts, or in other words to hydrolyze TNP-ATP to give equilmolar amounts of picric acid (TNP) and ATP, TNP-ATP should be treated with 1 M HCl at 100 degrees Celsius for 1.5 hours. This is because if TNP-ATP is acidified under mild conditions, it results in the opening of the dioxolane ring attached to the 2’-oxygen, leaving a 3’O-TNP derivative as the only product.
The post-bioprinting process is necessary to create a stable structure from the biological material. If this process is not well-maintained, the mechanical integrity and function of the 3D printed object is at risk. To maintain the object, both mechanical and chemical stimulations are needed. These stimulations send signals to the cells to control the remodeling and growth of tissues. In addition, in recent development, bioreactor technologies have allowed the rapid maturation of tissues, vascularization of tissues and the ability to survive transplants. Bioreactors work in either providing convective nutrient transport, creating microgravity environments, changing the pressure causing solution to flow through the cells, or adding compression for dynamic or static loading. Each type of bioreactor is ideal for different types of tissue, for example compression bioreactors are ideal for cartilage tissue.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.